These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9428467)

  • 1. Cyclosporine and lipid peroxidation.
    Kasiske BL
    Am J Kidney Dis; 1998 Jan; 31(1):149-51; discussion 151-4. PubMed ID: 9428467
    [No Abstract]   [Full Text] [Related]  

  • 2. Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients.
    van den Dorpel MA; Ghanem H; Rischen-Vos J; Man in't Veld AJ; Jansen H; Weimar W
    Kidney Int; 1997 May; 51(5):1608-12. PubMed ID: 9150480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of cyclosporin and tacrolimus on lipoprotein oxidation after renal transplantation].
    Martínez Castelao A; Ramos R; Serón D; Gil-Vernet S; Fiol C; Gómez-Gerique N; Yzaguirre MT; Hurtado I; Sabaté I; Alsina J; Grinyó JM
    Nefrologia; 2002; 22(4):364-9. PubMed ID: 12369128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.
    Sandborn WJ
    Am J Gastroenterol; 1996 Mar; 91(3):423-33. PubMed ID: 8633486
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma and low-density lipoprotein lipid peroxidation in cyclosporine A-treated children after liver transplant.
    Granot E; Shemesh P; Rivkin L; Kohen R
    Transplant Proc; 1998 Dec; 30(8):4057-9. PubMed ID: 9865293
    [No Abstract]   [Full Text] [Related]  

  • 6. Low-density lipoprotein composition and oxidation are not influenced by calcineurin inhibitors in renal transplant patients.
    Morena M; Vela C; Garrigue V; Catanzano J; Descomps B; Cristol JP; Mourad G
    Transplant Proc; 2000 Dec; 32(8):2785-6. PubMed ID: 11134805
    [No Abstract]   [Full Text] [Related]  

  • 7. Cyclosporin A does not increase the oxidative susceptibility of low density lipoprotein in vitro.
    Devaraj S; Li DJ; Vazquez M; Jialal I
    Free Radic Biol Med; 1999 Apr; 26(7-8):1064-8. PubMed ID: 10232852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients.
    Varghese Z; Fernando RL; Turakhia G; Psimenou E; Brunton C; Fernando ON; Davenport A; Burns A; Sweny P; Powis SH; Moorhead JF
    Transplant Proc; 1998 Aug; 30(5):2043-6. PubMed ID: 9723384
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunosuppressive agents in dermatology.
    Ho VC; Zloty DM
    Dermatol Clin; 1993 Jan; 11(1):73-85. PubMed ID: 8435920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress with cyclosporine-sparing regimens.
    Grinyó JM
    Transplant Proc; 1999 Dec; 31(8A):11S-16S. PubMed ID: 10616555
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunosuppressive treatment of ulcerative colitis].
    Shiratori T; Katsumata S; Miyaoka M; Saito T
    Nihon Rinsho; 1999 Nov; 57(11):2486-9. PubMed ID: 10572417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic monitoring of immunosuppressive drugs.
    Yatscoff RW; Langman LJ; LeGatt DF
    Transplant Proc; 1996 Dec; 28(6):3013-5. PubMed ID: 8962169
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation.
    Marcén R; Galeano C; Fernández-Rodriguez A; Jiménez-Alvaro S; Teruel JL; Rivera M; Burgos FJ; Quereda C
    Transplant Proc; 2010 Oct; 42(8):3055-7. PubMed ID: 20970609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid profile in renal transplant recipients under various immunosuppressive regimens.
    Montagnino G; Tarantino A; Aroldi A; Banfi G; Cesana B; Ponticelli C
    Transplant Proc; 1994 Oct; 26(5):2634-6. PubMed ID: 7940821
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunocompetence assay for net effect of combined immunosuppression.
    Nagashima N; Shalabi A; Watanabe T; Ogawa N; Koyama I; Kyo S; Burdick JF
    Transplant Proc; 2001 May; 33(3):2350-1. PubMed ID: 11377556
    [No Abstract]   [Full Text] [Related]  

  • 16. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
    Friemann S; Feuring E; Padberg W; Ernst W
    Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
    [No Abstract]   [Full Text] [Related]  

  • 17. Tacrolimus, cyclosporine and plasma lipoproteins in renal transplant recipients.
    Venkiteswaran K; Sgoutas DS; Santanam N; Neylan JF
    Transpl Int; 2001 Dec; 14(6):405-10. PubMed ID: 11793038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
    Gracida C; Melchor JL
    Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
    Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
    Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
    [No Abstract]   [Full Text] [Related]  

  • 20. Omission of azathioprine and mycophenolate mofetil in immunosuppressive regimen in kidney transplantation.
    Taheri M; Pourmand G; Mehrsai AR; Mansoori D
    Transplant Proc; 2003 Nov; 35(7):2752-3. PubMed ID: 14612105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.